S. Kostense

发表

HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

C. Hallahan, S. Migueles, J. Metcalf, 2002, Nature Immunology.

Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins

S. Kostense, W. Jiskoot, D. Weinbuch, 2013, Pharmaceutical Research.

Challenges of immunogenicity assays for vaccines.

S. Kostense, J. Hendriks, 2012, Bioanalysis.

High responsiveness of HLA‐B57‐restricted Gag‐specific CD8+ T cells in vitro may contribute to the protective effect of HLA‐B57 in HIV‐infection

S. Kostense, F. Miedema, N. Nanlohy, 2005, European journal of immunology.

First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity.

S. Kostense, C. Rupprecht, G. Weverling, 2008, Vaccine.

maturation: CD27 might provide a clue

D. Baarle, S. Kostense, F. Miedema, 2002 .

Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division.

S. Kostense, F. Miedema, R. V. van Lier, 1999, International immunology.

Immunogenicity of Recombinant Adenovirus Serotype 35 Vaccine in the Presence of Pre-Existing Anti-Ad5 Immunity1

S. Kostense, M. Lifton, N. Letvin, 2004, The Journal of Immunology.

Neutralizing Antibodies and CD8+ T Lymphocytes both Contribute to Immunity to Adenovirus Serotype 5 Vaccine Vectors

S. Kostense, M. Lifton, N. Letvin, 2004, Journal of Virology.

Pre-Existing Anti-Ad5 Immunity Serotype 35 Vaccine in the Presence of Immunogenicity of Recombinant Adenovirus

Jaap, Newberg, S. Kostense, 2004 .

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

B. Berkhout, S. Kostense, G. Weverling, 2004, AIDS.

Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

S. Kostense, P. Quax, M. Havenga, 2003, Journal of Virology.

Induction of CAMEL/NY-ESO-ORF2-specific CD8+ T cells upon stimulation with dendritic cells infected with a modified Ad5 vector expressing a chimeric Ad5/35 fiber

S. Kostense, M. Griffioen, M. Havenga, 2004, Cancer Gene Therapy.

A sensitive cell-based assay for the detection of residual infectious West Nile virus.

S. Kostense, G. Weverling, J. Lewis, 2007, Vaccine.

T cell expansions in lymph nodes and peripheral blood in HIV-1-infected individuals: effect of antiretroviral therapy

S. Kostense, P. Reiss, S. Danner, 2001, AIDS.

A Peptide-Based Plasmodium falciparum Circumsporozoite Assay To Test for Serum Antibody Responses to Pre-Erythrocyte Malaria Vaccines

S. Kostense, K. Radošević, J. Goudsmit, 2011, Clinical and Vaccine Immunology.

An adenoviral type 5 vector carrying a type 35 fiber as a vaccine vehicle: DC targeting, cross neutralization, and immunogenicity.

S. Kostense, A. Osterhaus, A. Zakhartchouk, 2004, Vaccine.

Longitudinal Phenotypic Analysis of Human Immunodeficiency Virus Type 1-Specific Cytotoxic T Lymphocytes: Correlation with Disease Progression

S. Kostense, F. Miedema, G. Ogg, 1999, Journal of Virology.

Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors

Jaap Goudsmit, Stefan Kostense, S. Kostense, 2003, Journal of Clinical Microbiology.

Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma.

D. Baarle, S. Kostense, F. Miedema, 2001, Blood.

Validation of the Rapid Fluorescent Focus Inhibition Test for Rabies Virus-Neutralizing Antibodies in Clinical Samples

S. Kostense, C. Hanlon, G. Weverling, 2012, Antimicrobial Agents and Chemotherapy.

Persistent numbers of tetramer+ CD8(+) T cells, but loss of interferon-gamma+ HIV-specific T cells during progression to AIDS.

S. Kostense, F. Miedema, N. Nanlohy, 2002, Blood.

High viral burden in the presence of major HIV‐specific CD8+ T cell expansions: evidence for impaired CTL effector function

Stefan Kostense, D. Baarle, S. Kostense, 2001, European journal of immunology.

Normalization of the CD4 T cell receptor repertoire after evolution of syncytium-inducing HIV-1 variants.

H. Schuitemaker, S. Kostense, F. Miedema, 2000, AIDS.

Diversity of the T‐cell receptor BV repertoire in HIV‐1‐infected patients reflects the biphasic CD4+ T‐cell repopulation kinetics during highly active antiretroviral therapy

S. Kostense, S. Danner, J. Teale, 1998, AIDS.

A fit-for-purpose strategy for the risk-based immunogenicity testing of biotherapeutics: a European industry perspective.

Daniel Kramer, Claudia Berger, Cathelijne Kloks, 2015, Journal of immunological methods.

Interleukin 12 administration enhances Th1 activity but delays recovery from influenza A virus infection in mice.

S. Kostense, D. Zander, B. Bender, 1998, Antiviral research.

Characterization of virus-specific CD8(+) effector T cells in the course of HIV-1 infection: longitudinal analyses in slow and rapid progressors.

S. Kostense, F. Miedema, D. van Baarle, 2004, Clinical immunology.

Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue.

Stefan Kostense, S. Kostense, F. Miedema, 2002, Trends in immunology.

Functional restoration of human immunodeficiency virus and Epstein‐Barr virus‐specific CD8+ T cells during highly active antiretroviral therapy is associated with an increase in CD4+ T cells

D. Baarle, S. Kostense, F. Miedema, 2002, European journal of immunology.

Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals

D. Baarle, S. Kostense, A. McMichael, 2001 .

HIV-specific T cells during progression to AIDS + γ Persistent numbers of tetramer+ CD8+ T cells, but loss of interferon-

D. Baarle, S. Kostense, F. Miedema, 2013 .

Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study

Albert Hofman, Silvan Licher, Reem Waziry, 2020, Brain : a journal of neurology.

Lack of Epstein-Barr virus- and HIV-specific CD27− CD8+ T cells is associated with progression to viral disease in HIV-infection

S. Kostense, F. Miedema, G. Ogg, 2002, AIDS.

Preclinical Models Used for Immunogenicity Prediction of Therapeutic Proteins

S. Kostense, W. Jiskoot, D. Weinbuch, 2013, Pharmaceutical Research.

Intraspecies variation in lethal body burdens of narcotic compounds

S. Kostense, A. Opperhuizen, D. Sijm, 1995 .

Mechanisms of decreasing HIV-1 specific CD8+ T cell activity during progression to AIDS

S. Kostense, 2001 .

Stability studies of binding and functional anti-vaccine antibodies.

S. Kostense, A. Versteilen, F. Tirion, 2014, Bioanalysis.

Validation of Adapted Neutralization Assays Developed to Discriminate Anti-Rabies Virus Activity of Two Different Anti-Rabies Virus Monoclonal Antibodies Administered as a Combination

S. Kostense, W. Marissen, B. Boulanger, 2023, Biologics.

Replication-Deficient Human Adenovirus Type 35 Vectors for Gene Transfer and Vaccination: Efficient Human Cell Infection and Bypass of Preexisting Adenovirus Immunity

S. Kostense, P. Quax, M. Havenga, 2003, Journal of Virology.

Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma.

D. Baarle, S. Kostense, F. Miedema, 2001, Blood.